A Phase 2 interventional study of NL005 Middle Dose and NL005 High Dose in Acute Myocardial Infarction, sponsored by Beijing Northland Biotech. Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-21.
Sponsored by Beijing Northland Biotech. Co., Ltd. · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 196 studies in Myocardial Infarction with a site in China — 64 open to participants now, 73 under way, 8 of them phase 3. Myocardial Infarction · China.
Among the 196 studies in Myocardial Infarction with a site in China, this one is the 89th largest by enrollment of the 107 interventional ones that give a count, is one of 13 that started in 2022, is one of 4 in phase 2, and was the 124th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →64 of the 196 studies in Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Beijing Hospital · Sites in China
Ages 30–75
Peking University Third Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Beijing Anzhen Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
196 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 22 · Phase 4 32
First in 1999; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is below the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 366 across the 107 interventional studies, 1,000 across the 89 observational. Of the 74 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 196 have an industry lead sponsor. The 10 most frequent:
Beijing Northland Biotech. Co., Ltd. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Beijing Northland Biotech. Co., Ltd. has 2 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
21 of the studies in Myocardial Infarction with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07381803Phase 3Second Affiliated Hospital, Zhejiang University, School of MedicineThe Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction | 2026-12 |
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT07320625Phase 3Shanghai Zhongshan HospitalEfficacy of Montelukast on STEMl Patients | 2027-02-01 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05891145Yangzhou UniversityRemimazolam for Postoperative Atrial Fibrillation | 2026-12 |
Add all 21 to your calendar (.ics) → With an account.
Among the 196 studies in Myocardial Infarction with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multicenter randomized double-blind placebo parallel control design was used in this study. The 90 participants were randomly assigned to placebo, 0.5μg/kg dose group, and 1.0μg/kg dose group in a ratio of 1:1:1. After randomization, subjects received the trial drug or placebo intravenously within 12 hours and on days 2 to 7 after PCI. The patients were observed 90 days after PCI.
Cardiovascular magnetic resonance imaging (CMR) was performed on day 5 and day 90 after PCI to evaluate myocardial infarction size, microvascular obstruction area, left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV). Physical examination, blood routine examination, and coagulation function examination were performed before the first dose, on the 7th, 30th, and 90th day after PCI. The examination before the first dose was conducted to accept the examination results from the current onset to the first dose.Electrocardiogram (ECG) was performed before the first dose, day 2, day 7, day 30, and day 90 after PCI, and the test results from the period after PCI to the first dose were received. Vital signs were examined before the first dose, day 1 to day 7, day 30, and day 90 after PCI, and the results of the examination from the first onset to the first dose were accepted during the examination before the first dose. Blood biochemical tests were performed before the first dose, from day 2 to day 4, day 7, day 30, and day 90 after PCI. The results of the examinations from the first onset to the first dose were accepted during the examination before the first dose. High-sensitivity troponin I(hs-cTnI) or troponin I(cTnI) and amino-terminal B-type natriuretic peptide precursor (NT-proBNP) or B-type natriuretic peptide (BNP) were tested before first administration and on days 2, 3, 4, and 7 after PCI. Examination results from the time after PCI to the time before initial administration; Creatine kinase isoenzyme (CK-MB) tests were performed before the first dose, 12 hours after the first dose, day 2 (if it coincided with 12 hours after the first dose, no repeat blood collection was required), day 3, and day 4. The test results from the period after PCI to the period before the first dose were accepted. Tumor markers were detected and immunogenic blood samples were collected before the first dose and on the 30th day after PCI. The tumor markers were examined before the first dose. Urine routine examination was performed before the first dose and on the 90th day after PCI. The examination before the first dose accepted the examination results from the onset of the disease to the first dose. Drug combinations, adverse events, and cardiovascular events were recorded during the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
meet one of the following conditions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
12 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 (intravenous injection),Day2-Day7 after PCI:0.5 ug/kg Recombinant Human Thymosin β4 (intravenous injection)
Drug: NL005 Middle Dose
12 hours after PCI: 1.0 ug/kg Recombinant Human Thymosin β4 (intravenous injection),Day2-Day7 after PCI:1.0 ug/kg Recombinant Human Thymosin β4 (intravenous injection)
Drug: NL005 High Dose
Patients in this treatment group will receive placebo respective. Continuous administration for 7 days.
Drug: Placebo
Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
Also known as: NL005( Middle Dose)
Patients in this treatment group will receive NL005 for 1.5 ug/kg respective.Continuous administration for 7 days.
Also known as: NL005( High Dose)
30 subjects will be randomly assigned to the placebo for 7 days
Percentage change of myocardial infarction area
The percentage of myocardial infarction area was defined as the percentage of CMR delayed enhancement area in the entire left ventricular myocardium as measured by plane geometry of computer-assisted enhanced myocardium.Percentage change of myocardial infarction size =D5 percentage of myocardial infarction size -D90 percentage of myocardial infarction size
Time frame: Day 5、Day 90
Myocardial mass (g)
Myocardial infarction area was defined as CMR delayed enhancement area, and myocardial mass (g) were calculated , and determined by plane geometry method of computer-aided enhanced myocardium. Myocardial infarction size change =D5 myocardial infarction size -D90 myocardial infarction size.
Time frame: Day 5、Day 90
Myocardial volume (ml)
Myocardial infarction area was defined as CMR delayed enhancement area, and volume (ml) were calculated, and determined by plane geometry method of computer-aided enhanced myocardium.Myocardial infarction size change =D5 myocardial infarction size -D90 myocardial infarction size.
Time frame: Day 5、Day 90
Myocardial microvessel obstruction area change value
Myocardial microvessel obstruction area change value =D5 microvessel obstruction area -D90 microvessel obstruction area
Time frame: Day 5、Day 90
The change of CK-MB before and after administration
CK-MB change value = CK-MB value before administration - CK-MB value after administration
Time frame: Before the first dose, 12 hours after the first dose, day 2, day 3, day 4
The area under the CK-MB curve within 4 days
CK-MB change value = CK-MB value before administration - CK-MB value after administration
Time frame: Before the first dose, 12 hours after the first dose, day 2, day 3, day 4
Changes of left ventricular ejection fraction (LVEF)
Left ventricular ejection fraction (LVEF) change =D90 LVEF-D5 LVEF
Time frame: Day 5、Day 90
Changes of left ventricular end-systolic volume (LVESV)
Left ventricular end-systolic volume (LVESV) change =D90 LVESV-D5 LVESV
Time frame: Day 5、Day 90
Changes of left ventricular end-diastolic volume (LVEDV)
Left ventricular end-diastolic volume (LVEDV) change = D90 LVEDV-D5 LVEDV
Time frame: Day 5、Day 90
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2022 to primary completion in May 2023, 10 months.
Of 45 phase 2 interventional studies under Myocardial Infarction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Northland Biotech. Co., Ltd.